RecruitingNot ApplicableNCT06277466

Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls

Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Enrollment

300 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Genetic Mutations Type 2 Diabetes Mellitus Gene Polymorphisms Susceptibility, Genetic

Summary

In this study, investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression. Participants (T2DM patients and controls) were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes.

Eligibility

Min Age: 25 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether genetic mutations linked to Type 2 diabetes (T2DM) affect how certain genes are expressed in pancreatic tissue. It aims to understand why some people are more susceptible to developing diabetes at a molecular level. **You may be eligible if...** - You are a newly diagnosed Type 2 diabetes patient aged 25-70, not yet on medication, with HbA1c between 7-12%, and a stable body weight - You are a healthy volunteer aged 25-60 with normal BMI and no significant health conditions, OR - You are a surgical patient aged 20-80 having part or all of your pancreas removed for a confirmed pancreatic condition **You may NOT be eligible if...** - You have previously taken diabetes medications - You have had prior pancreatic surgery - You have severe organ damage or take medications that affect pancreatic function Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs

Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.

DRUGFresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs

The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection. In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.